Global bladder cancer market was valued at $5,920 million in 2025 and is growing at a CAGR of 6.4% during the forecast period (2026-2035). Active interactions with regulatory agencies and streamlined submission pathways promote the market growth of innovative therapies by enabling quicker market entry. This trend is reflected in ongoing regulatory engagements that focus on optimizing approval processes and facilitating access to advanced treatment options for patients with unmet medical needs. For instance, in January 2026, ImmunityBio is in talks with the FDA about possibly resubmitting its supplemental Biologics License Application (sBLA) for ANKTIVA to treat BCG-unresponsive papillary non-muscle invasive bladder cancer (NMIBC). The FDA requested additional information, which does not require new clinical trials, to aid in their evaluation, with the company set to provide this data within 30 days. Long-term studies have indicated a 96% bladder cancer-specific survival rate and over 80% bladder preservation at three years among 80 patients. ANKTIVA has been launched in the US, along with expanded approvals in the UK and Saudi Arabia, and conditional EU approval. Recent discussions with the FDA highlighted high disease-specific survival rates and a favorable safety profile, addressing current treatment standards and challenges faced by BCG-unresponsive patients.
Browse the full report description of “Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other Rare Types) By Diagnosis Method (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (Ivp), and Other) By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and other) Forecast, 2026-2035” of https://www.omrglobal.com/industry-reports/bladder-cancer-market
Leading Players Shaping Innovation in the Bladder Cancer Market
The key players in the bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb Co., Novartis AG, Pfizer Inc., Roche Holding AG (Genentech, Inc.), among others. These companies are driving innovation in digital health solutions such as telemedicine, electronic health records, remote patient monitoring, and AI-powered clinical tools, shaping the future of healthcare delivery globally.
- In September 2025, the FDA approved the gemcitabine intravesical system (Inlexzo) for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. The system includes a urinary catheter for administration. Its efficacy was tested in the SunRISe-1 trial with 83 patients, receiving treatment every 3 weeks for 6 months, then every 12 weeks for up to 18 months. Tumor status was monitored via cystoscopy and urine cytology. Primary outcomes included complete response (CR) and duration of response (DOR) based on central pathology review. Risks noted in the prescribing information include bladder perforation, potential for metastatic cancer with delayed cystectomy, MRI safety, and embryo-fetal toxicity.
- In November 2025, the US FDA has approved PADCEV (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab) as the first perioperative treatment regimen for patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy. This approval is based on the Phase 3 EV-303 trial, which demonstrated a 60% reduction in disease recurrence, progression, or death and a 50% reduction in mortality compared to surgery alone. The treatment combines a Nectin-4-directed antibody-drug conjugate with a PD-1 inhibitor and continues after cystectomy as adjuvant therapy. The safety profile was consistent with previous reports, with common adverse reactions including increased glucose, fatigue, and peripheral neuropathy. Grade ? 3 adverse events were higher in the combination group (71.3%) compared to surgery alone (45.9%).
- In December 2025, the FDA approved pembrolizumab (Keytruda, Keytruda Qlex) in combination with enfortumab vedotin-ejfv (Padcev) for adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin chemotherapy. This neoadjuvant treatment continues after cystectomy as adjuvant therapy. The decision was based on the KEYNOTE-905/EV-303 study, which involved 344 untreated MIBC patients eligible for radical cystectomy but unable or unwilling to undergo cisplatin-based treatment.
Market Coverage
- The market number available for – 2025-2035
- Base year- 2025
- Forecast period- 2026-2035
- Segment Covered-
- By Cancer Type
- By Diagnosis Method
- By Diagnosis Method
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape - AstraZeneca PLC, Bristol-Myers Squibb Co., Novartis AG, Pfizer Inc., Roche Holding AG (Genentech, Inc.), among others.
Key questions addressed by the report.
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Bladder Cancer Market Report Segment
By Cancer Type
- Transitional Cell Bladder Cancer/ Urothelial Carcinoma
- Squamous Cell Bladder Cancer
- Adenocarcinoma
- Other Rare Types (Sarcomas, Carcinoma in Situ)
By Diagnosis Method
- Cystoscopy
- Biopsy
- Urinalysis
- Urine Cytology
- Intravenous Pyelogram (IVP)
- Others
By Diagnosis Method
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Surgery
- Other
Global Bladder Cancer Market Report Segment by Region
North America
Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- ASEAN Economies
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/bladder-cancer-market